Clinical Trial

ASCERV Study: MRG003 Combined With QL1706 in Recurrent or Metastatic Cervical Cancer

Not Yet Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a single-arm, multicenter, phase II study designed to evaluate the efficacy and safety of MRG003, an anti-EGFR antibody-drug conjugate, in combination with QL1706, a PD-1/CTLA-4 bispecific antibody, in patients with recurrent or metastatic cervical cancer who have failed prior platinum-based therapy.
Protocol Amendment History 1 change
notable Sponsor changed: Second Affiliated Hospital, School of Medicine, Zhejiang University -> Second Affiliated Hospital, Zhejiang University, School of Medicine 2026-08-09
Trial Details
NCT Number NCT07542717
Lead Sponsor Second Affiliated Hospital, School of Medicine, Zhejiang University
Conditions Recurrent or Metastatic Cervical Cancer
Enrollment 41 participants
Start Date 2026-04-10
Primary Completion 2028-03-31 (estimated)
Study Completion 2030-03-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-21